Sign In
Buy ZYME
$22.86
-0.260 (-1.12%)
At Close: Jul 24, 2026
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
06:00am, Thursday, 16'th Jul 2026
VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipe
Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharma
08:30am, Wednesday, 01'st Jul 2026
Zymeworks Inc. acquires Theravance Biopharma for $929M, pivoting to a hybrid biotech and royalty/cash-flow platform anchored by Yupelri. ZYME gains durable, growing cash flows—$60M annually from Yup
Theravance Stock Down 3% After Zymeworks Announces Buyout
09:55am, Tuesday, 30'th Jun 2026
TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic review triggered by its failed ampreloxetine program.
Zymeworks Inc. (ZYME) M&A Call Transcript
03:32pm, Monday, 29'th Jun 2026
Zymeworks Inc. (ZYME) M&A Call Transcript
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
09:20am, Monday, 29'th Jun 2026
Zymeworks Inc. (NASDAQ:ZYME) said Monday it has agreed to acquire Theravance Biopharma Inc. (NASDAQ:TBPH) in an all-cash transaction valued at about $929 million.
Zymeworks strikes $929 million deal for Theravance Biopharma
06:13am, Monday, 29'th Jun 2026
Drugmaker Zymeworks said on Monday it will buy Theravance Biopharma in a $929 million deal.
Zymeworks to Acquire Theravance Biopharma, Inc.
06:00am, Monday, 29'th Jun 2026
VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) (the “Company”), a biotechnology company managing a portfolio of licensed healthcare assets and develop
Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery
08:00am, Thursday, 18'th Jun 2026
Vancouver-based biotech companies Gandeeva Therapeutics and Zymeworks have partnered to generate cryo-EM–based structural data to augment antibody drug discovery. VANCOUVER, BC, June 18, 2026 /PRNew
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
06:05pm, Sunday, 14'th Jun 2026
VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipe
Zymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC Optionality
07:30am, Friday, 22'nd May 2026
Zymeworks is transitioning into an oncology royalty platform with a robust internal discovery engine, offering a differentiated risk-reward profile versus traditional biotech peers. ZYME's balance she
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
04:05pm, Thursday, 14'th May 2026
VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipel
Zymeworks Announces Participation in Upcoming Investor Conferences
06:00am, Wednesday, 13'th May 2026
VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipel
Zymeworks Q1 Earnings Call Highlights
05:07am, Saturday, 09'th May 2026
Zymeworks NASDAQ: ZYME reported a wider first-quarter loss as revenue declined from year-earlier milestone payments, while management highlighted regulatory catalysts for zanidatamab, progress across
Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript
12:21am, Saturday, 09'th May 2026
Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
08:11pm, Thursday, 07'th May 2026
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.3 per share a year ago.
